Martinon Frédéric, Brochard Patricia, Ripaux Maryline, Delache Benoît, Aurégan Gwenaelle, Vaslin Bruno, Le Grand Roger
CEA, Service d'Immuno-Virologie, DSV, iMETI, 18 route du Panorama, Fontenay Aux Roses, France.
Vaccine. 2008 Jan 24;26(4):532-45. doi: 10.1016/j.vaccine.2007.11.025. Epub 2007 Dec 3.
Using the experimental infection of cynomolgus macaques with simian immunodeficiency virus (SIV) as a model of human immunodeficiency virus infection in humans, we studied the immunogenicity and protective efficacy of a vaccine strategy combining DNA, the modified recombinant vaccinia virus strain Ankara (MVA) and Semliki Forest virus (SFV) expressing gag, pol, env, tat, rev and nef from SIV. Although this immunization strategy induced moderate immune responses, the control of pathogenic SIVmac251 infection following mucosal challenge was clearly improved by vaccination. The viral load in vaccinated animals was reduced by 2 logs during the acute phase of infection and, in five of the six macaques, viral load fell below the detection limit at set point. No correlates of immune protection were identified, but SIV-specific T-cell responses were detected earlier in vaccinated animals than in controls. These results highlight the power of live attenuated virus vectors for vaccination strategies.
我们以食蟹猕猴感染猿猴免疫缺陷病毒（SIV）作为人类免疫缺陷病毒感染的模型，研究了一种联合使用DNA、改良重组安卡拉痘病毒（MVA）和表达SIV的gag、pol、env、tat、rev和nef的辛德毕斯病毒（SFV）的疫苗策略的免疫原性和保护效力。尽管这种免疫策略诱导了适度的免疫反应，但接种疫苗明显改善了黏膜攻击后致病性SIVmac251感染的控制。在感染急性期，接种疫苗动物的病毒载量降低了2个对数，并且在6只猕猴中的5只中，病毒载量在设定点时降至检测限以下。未发现免疫保护的相关因素，但接种疫苗的动物比对照动物更早检测到SIV特异性T细胞反应。这些结果突出了减毒活病毒载体在疫苗策略中的作用。
